STOCK TITAN

NeuroMetrix, Inc. - NURO STOCK NEWS

Welcome to our dedicated page for NeuroMetrix news (Ticker: NURO), a resource for investors and traders seeking the latest updates and insights on NeuroMetrix stock.

NeuroMetrix, Inc., based in Waltham, Massachusetts, is a leading innovator in the healthcare sector, focusing on the development and commercialization of neurotechnology devices. Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and Technology, the company uniquely combines bioelectrical and digital medicine to address chronic health conditions such as chronic pain, sleep disorders, and diabetes.

The company's flagship product, Quell®, is a wearable neuromodulation platform that offers drug-free pain relief through clinical-grade neurostimulation. Quell® is designed to help individuals suffering from chronic back pain, arthritic pain, nerve pain, and other chronic pain conditions manage their symptoms effectively. Its user-friendly app further aids patients in reclaiming their quality of life.

Another notable product is DPNCheck®, a point-of-care screening test designed for peripheral neuropathy, particularly in diabetic patients. This device has become an essential tool for early diagnosis and management of neuropathy.

NeuroMetrix continues to invest in research and development, maintaining several pipeline programs aimed at expanding their product offerings and improving existing technologies. The company’s current projects include refining their wearable devices to integrate more advanced features, enhancing user experience through mobile apps, and leveraging cloud-based systems for data analysis and management.

Additionally, NeuroMetrix has established significant partnerships and collaborations to expand its market reach and enhance its technological capabilities. Despite the challenges highlighted in recent news, including shareholder concerns about stock valuation and leadership, the company remains focused on delivering innovative healthcare solutions.

For more updates and detailed information on NeuroMetrix's performance, events, and developments, visit NeuroMetrix.com.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
-
Rhea-AI Summary

NeuroMetrix, Inc. (Nasdaq: NURO) will showcase Quell Fibromyalgia at the American Academy of Pain Medicine's 39th Annual Meeting from March 23-26, 2023, in Ft. Lauderdale, FL. The company will also present two scientific posters on new data related to Quell's effectiveness in treating fibromyalgia, which affects up to 15 million adults in the U.S. Quell is the only FDA-authorized device designed to alleviate fibromyalgia symptoms. Key findings from studies suggest Quell may improve balance and treatment response among patients without weather sensitivity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
Rhea-AI Summary

NeuroMetrix (NURO) reported Q4 2022 revenues of $1.8 million, up 1.5% YoY, driven by an 18.1% rise in DPNCheck® sales. Gross profit fell 1% to $1.2 million, with a gross margin of 66.6%. Operating expenses decreased to $2.1 million from $2.2 million, though R&D costs dropped due to increased personnel spending. The net loss improved to $0.7 million ($0.09 per share) from $1 million ($0.15 per share) in Q4 2021. For the full year, total revenues reached $8.3 million, with a net loss of $4.4 million compared to $2.3 million last year. Major product launches included Quell Fibromyalgia and DPNCheck 2.0, signaling a strategic shift toward commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
-
Rhea-AI Summary

NeuroMetrix, Inc. (NASDAQ: NURO) will announce its 2022 fourth quarter and year-end financial results before the market opens on February 23, 2023. A conference call is scheduled for 8:00 a.m. ET on the same day to discuss these results and relevant business developments. Participants can register in advance for the earnings call and will receive dial-in details. NeuroMetrix focuses on innovative medical devices aimed at improving health outcomes for neurological disorders and pain syndromes, including products like DPNCheck®, ADVANCE®, and Quell® Fibromyalgia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
-
Rhea-AI Summary

NeuroMetrix announces the launch of DPNCheck 2.0, a point-of-care device designed to detect peripheral neuropathy. This innovative device uses advanced nerve conduction technology for quick screening and offers a user-friendly touchscreen interface with improved features. Notably, peripheral neuropathy affects up to 30% of the Medicare-aged population, prompting healthcare providers to focus on early detection to prevent severe complications like foot ulcers. DPNCheck 2.0 will be showcased at the Medicare Advantage Leadership Innovations National Conference on January 24-25, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
none
Rhea-AI Summary

NeuroMetrix, Inc. (Nasdaq: NURO) will present its innovative device, Quell Fibromyalgia, at the ACR Convergence 2022 from November 12 to 14 in Philadelphia. This wearable neuromodulation technology is the first FDA-authorized device aimed at alleviating fibromyalgia symptoms. Fibromyalgia affects approximately 5 to 15 million U.S. adults, characterized by chronic pain and fatigue. Quell Fibromyalgia, part of NeuroMetrix's prescription wearable neurotherapeutics, supports patients with high pain sensitivity, offering a potential breakthrough in treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.7%
Tags
none
-
Rhea-AI Summary

NeuroMetrix (Nasdaq: NURO) has launched the Quell® Fibromyalgia device through its Pathfinder Program. This device is the first FDA-authorized medical device aimed at alleviating fibromyalgia symptoms. The Pathfinder Program, beginning December 1, 2022, will involve 25 key-opinion leaders in fibromyalgia to refine its commercial approach ahead of a full launch expected in Q2 2023. Quell Fibromyalgia utilizes TENS technology and is designed for adults with high pain sensitivity, offering a non-invasive treatment option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.19%
Tags
none
-
Rhea-AI Summary

NeuroMetrix (NURO) reported Q3 2022 revenues of $2.0 million, a decline of 4.7% from Q3 2021. DPNCheck® sales fell by 6% due to reduced international orders. Gross profit decreased to $1.3 million, with a margin rate dropping to 64.8%.

Operating expenses rose to $3.0 million, leading to a net loss of $1.6 million ($0.23 per share). The company is preparing for a Q4 2022 launch of Quell Fibromyalgia, the first FDA-authorized device for this condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.43%
Tags
Rhea-AI Summary

NeuroMetrix (Nasdaq: NURO) will release its 2022 Q3 financial results on Oct 20, 2022, before market opening. A conference call will occur at 8:00 a.m. ET on the same day to discuss these results and other business developments. Participants can register in advance to join the call and ask questions. The company's focus is on enhancing health through innovative medical devices targeting neurological disorders. Its product line includes DPNCheck®, ADVANCE®, and Quell® Fibromyalgia, addressing various health concerns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags

FAQ

What is the current stock price of NeuroMetrix (NURO)?

The current stock price of NeuroMetrix (NURO) is $3.92 as of December 24, 2024.

What is the market cap of NeuroMetrix (NURO)?

The market cap of NeuroMetrix (NURO) is approximately 8.0M.

What does NeuroMetrix, Inc. specialize in?

NeuroMetrix specializes in developing neurotechnology devices to address chronic pain, sleep disorders, and diabetes.

What are the main products offered by NeuroMetrix?

The main products are Quell®, a wearable neuromodulation platform, and DPNCheck®, a point-of-care screening test for peripheral neuropathy.

Where is NeuroMetrix located?

NeuroMetrix is located in Waltham, Massachusetts.

When was NeuroMetrix founded?

NeuroMetrix was founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and Technology.

What is Quell® used for?

Quell® is used for drug-free pain relief through clinical-grade neurostimulation, effective for chronic back pain, arthritic pain, nerve pain, and other chronic pain conditions.

What is DPNCheck®?

DPNCheck® is a point-of-care screening test for peripheral neuropathy, which is particularly essential for diabetic patients.

Does NeuroMetrix have any ongoing research projects?

Yes, NeuroMetrix maintains active research efforts and has several pipeline programs aimed at expanding their product offerings and improving existing technologies.

How can I get more information about NeuroMetrix?

For more detailed information, you can visit the company's official website at www.NeuroMetrix.com.

What recent achievements has NeuroMetrix announced?

Recently, NeuroMetrix announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.

What challenges is NeuroMetrix currently facing?

NeuroMetrix is currently addressing shareholder concerns about stock valuation, leadership decisions, and overall strategic direction.

NeuroMetrix, Inc.

Nasdaq:NURO

NURO Rankings

NURO Stock Data

8.01M
1.59M
25.45%
3.01%
2.08%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
WALTHAM